Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo (Q40235490)

18 September 2017

Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo (English)

1 reference

18 September 2017

1 reference

Hirohisa Yano

1

1 reference

18 September 2017

Sachiko Ogasawara

2

1 reference

18 September 2017

Seiya Momosaki

3

1 reference

18 September 2017

Jun Akiba

4

1 reference

18 September 2017

Sakiko Kojiro

5

1 reference

18 September 2017

Suguru Fukahori

6

1 reference

18 September 2017

Hironori Ishizaki

7

1 reference

18 September 2017

Keitaro Kuratomi

8

1 reference

18 September 2017

Yuji Basaki

9

1 reference

18 September 2017

Shinji Oie

10

1 reference

18 September 2017

Michihiko Kuwano

11

1 reference

18 September 2017

Masamichi Kojiro

12

1 reference

18 September 2017

language of work or name

1 reference

1 October 2006

1 reference

18 September 2017

1 reference

18 September 2017

26

1 reference

18 September 2017

8

1 reference

18 September 2017

964-975

1 reference

How cells respond to interferons

18 September 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01321.X

Cytokine therapeutics: lessons from interferon alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01321.X

Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01321.X

Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01321.X

Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01321.X

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01321.X

Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01321.X

Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01321.X

Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01321.X

Interferon-alphaCon1 suppresses proliferation of liver cancer cell lines in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01321.X

Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01321.X

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01321.X

Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01321.X

Peginterferon alfa-2b plus ribavirin for naïve patients with genotype 1 chronic hepatitis C: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01321.X

A human combined hepatocellular and cholangiocarcinoma cell line (KMCH-2) that shows the features of hepatocellular carcinoma or cholangiocarcinoma under different growth conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01321.X

Identification of a caspase-9 substrate and detection of its cleavage in programmed cell death during mouse development

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01321.X

Antiproliferative effects of interferon-alphaCon1 on ovarian clear cell adenocarcinoma in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01321.X

Interferon-α receptor expression and regulation in chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01321.X

A flow cytometric method for determination of the interferon receptor IFNAR2 subunit in peripheral blood leukocyte subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01321.X

Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01321.X

Antiproliferative effects of 5-fluorouracil and interferon-alpha in combination on a hepatocellular carcinoma cell line in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1478-3231.2006.01321.X

10.1111/J.1478-3231.2006.01321.X

21 January 2018

Identifiers

DOI

1 reference

18 September 2017

1 reference